Germany’s Merck eyes life science deals, but muted 2026 outlook knocks shares
By Marleen Kaesebier (Reuters) -German pharmaceuticals and technology company Merck KGaA gave a guidance for 2026 that sent its shares falling during its capital markets day on Thursday, wiping out their earlier gains that had been buoyed by more upbeat mid-term commentary. Merck’s life science and electronics units are expected to improve gradually next year, …
Germany’s Merck eyes life science deals, but muted 2026 outlook knocks shares Read More »









